Generalforsamling - frist for fremsættelse af emner
Tivoli A/S afholder ordinær generalforsamling torsdag den 27. april 2023, kl. 13:30 i Tivolis Koncertsal.
Forslag fra aktionærer til emner behandlet på generalforsamlingen skal fremsættes senest onsdag den 15. marts 2023.
Eventuelle forslag sendes skriftligt til firstname.lastname@example.org.
Tivolis aktionærer vil forventeligt modtage indkaldelse til generalforsamlingen i slutningen af marts 2023.
Med venlig hilsen
Susanne Mørch Koch
Kontaktperson: Juridisk Direktør, Caroline Reiler: email@example.com
Vedhæftet filFor at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Novo Nordisk A/S - share repurchase programme27.3.2023 16:07:25 CEST | Press release
Bagsværd, Denmark, 27March 2023 – On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 28 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme initiated 1 February 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.6 billion in the period from 1 February 2023 to 2 May 2023. Since the announcement 20 March, the following transactions have been made: Number of B sharesAverage purchase priceTransaction value, DKKAccumulated, last announcement3,025,1712,975,219,09720 March 202391,500987.8090,384,03221 March 202391,0001,000.2991,026,00422 March 202391,0001,017.9092,628,63523 March 202390,0001,025.7592,317,25224 March 202390
Acronis Earns 5-Star Rating in 2023 CRN® Partner Program Guide27.3.2023 16:00:00 CEST | Press release
This exclusive recognition is awarded to successful and committed channel-focused vendors in the IT space BURLINGTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Acronis, a global leader in cyber protection, today announced that CRN®, a brand of The Channel Company, has named the Acronis #CyberFit Partner Program with a prestigious 5-star rating in its 2023 Partner Program Guide. This annual guide offers essential information to solution providers such as managed service providers (MSPs), value-added resellers (VARs), systems integrators, and strategic service providers as they explore technology manufacturers’ partner programs to find the vendors that will best support their business needs. The 5-star rating is awarded to the companies that go above and beyond in their commitment to nurturing strong, profitable, successful channel partnerships. “We strive to make the Acronis #CyberFit Partner Program an easy, transparent, and powerful business development tool for our partners,” said Al
Kvika banki hf.: Annual General Meeting 30 March 2023 - Candidacy to the Board and amended proposals of the BoD27.3.2023 15:48:10 CEST | Press release
The deadline for candidacy to the Board expired on 25 March 2022. The following candidates have submitted their application for the Board of Directors at the AGM, to be held on 30 March, at 4:00 pm at Grand Hotel, Háteigur, Sigtún 28, 150 Reykjavík, also accessible online through Lumi AGM: In candidacy for the Board of Directors: Sigurður HannessonGuðmundur ÞórðarsonGuðjón ReynissonHelga Kristín AuðunsdóttirIngunn Svala Leifsdóttir In candidacy as alternate members: Helga Jóhanna OddsdóttirSigurgeir Guðlaugsson It is the assessment of the Board that all candidacies are valid in accordance with Act No. 2/1995 respecting Public Limited Companies. According to the company’s articles of association the Board of Directors shall consist of five members and two alternate members. As no further candidates have applied for the Board of Directors or as alternate members, the candidates are self-elected. Attention is drawn to an amendment proposal from Gildi Pension Fund regarding the wording of
07/2023 Green Hydrogen Systems - Financial calendar 2023 (updated)27.3.2023 15:45:00 CEST | Press release
Company announcement 07/2023 Green Hydrogen Systems updatesfinancial calendar for 2023 Kolding, Denmark, 27 March 2023 – Green Hydrogen Systems A/S hereby updates its financial calendar for 2023: Q1 2023 Trading Statement: 17 April 2023 (updated) Annual General Meeting: 18 April 2023 Q2 2023 Interim Report: 22 August 2023 Q3 2023 Trading Statement: 1 November 2023 For more info please contact: Investors: Jens Holm Binger, Head of Investor Relations, +45 6065 6525, firstname.lastname@example.org Media: Jesper Buhl, Head of Public Affairs and Media Relations, +45 5351 5295, email@example.com Green Hydrogen Systems in brief Green Hydrogen Systems is a clean technology company and a leading provider of standardised and modular electrolysers for the production of green hydrogen solely based on renewable energy. With its wide range of possible applications, green hydrogen plays a key role in the ongoing fundamental shift in our energy systems towards a net-zero emission society in 2050. As a result
NATALEE (TRIO033) Phase III trial demonstrates ribociclib significantly reduces the risk of recurrence for patients with early breast cancer, at interim analysis27.3.2023 15:28:42 CEST | Press release
EDMONTON, Alberta, March 27, 2023 (GLOBE NEWSWIRE) -- Translational Research In Oncology (TRIO) today announced positive topline results from NATALEE (TRIO033), a Novartis sponsored Phase III trial of ribociclib plus endocrine therapy (ET) as adjuvant treatment for patients with stages II and III early breast cancer (EBC) at risk of disease recurrence. NATALEE (TRIO033) met its primary endpoint at a pre-planned interim analysis, achieving a statistically significant improvement in invasive disease-free survival (iDFS) in women and men with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) EBC, when compared to ET alone. “At TRIO, we always strive to improve the lives of cancer patients by conducting clinical trials that might make a fundamental difference in outcomes. We are very proud of our collaboration with Novartis in the conduct of the NATALEE (TRIO033) trial. The results announced today are a significant step forward towards reducing the ris